Compare Nokia Corp (NOK) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nokia Corp vs Sanofi SA — how do they compare? Nokia Corp trades at $10.36 (market cap $56.99B), while Sanofi SA trades at $40.04 (market cap $95.18B). The key difference: Sanofi SA is the larger of the two by market cap, and Sanofi SA pays the higher dividend (6.01%). Which is the better fit depends on your goals — on Pluang, investors hold Nokia Corp for 66 Days and Sanofi SA for 94 Days on average.
| NOK | SNY | |
|---|---|---|
Market Cap | $56.99B | $95.18B |
Volume | 69,968,204 | 2,995,646 |
Sector | Technology | Health |
52-Week High | $16.83 | $52.34 |
52-Week Low | $5.18 | $39.51 |
Typical Hold Time | 66 Days | 94 Days |
Enterprise Value | $55.01B | $114.48B |
Dividend Yield | 1.61% | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nokia (NOK) trades at $10.36, down 2.45% on the day, with a bearish technical signal and neutral oscillators. The company reported mixed quarterly earnings, with a beat in Q2 2026 but a miss in Q1 2026. Revenue for 2025 was $19.89 billion, with a net income margin of 3.47%. Recent news highlights partnerships in AI and satellite communications, including an expanded collaboration with Microsoft and a defense-focused satellite venture with ICEYE.
The stock presents a valuation disconnect, with a high P/E of 75.09 but strong analyst optimism—61.5% recommend Buy, with a consensus price target of $17.50. Upside catalysts include AI infrastructure demand and strategic partnerships, while risks involve competitive pressures and volatile cash flows, evidenced by a net cash outflow of $1.16 billion in 2025.
Sanofi (SNY) trades at $40.07, down 0.32% on the day, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $1.21 exceeding the $1.10 estimate. Revenue for 2025 reached $46.72 billion, with a net income margin of 16.72%. Recent news highlights a significant $8 billion immunology alliance expansion with Regeneron, signaling strategic growth initiatives.
The outlook is mixed; solid profitability and a strategic partnership provide upside potential, but a projected net income decline to $4.0 billion in 2026 and bearish technical indicators pose risks. Analyst sentiment is cautiously optimistic with a 44% buy rating, though investors should monitor execution of new collaborations and patent expiration impacts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nokia Corp
Nokia is a leading vendor in the telecommunications equipment industry. The company's network business derives revenue from selling wireless and fixed-line hardware, software, and services. Nokia's technology segment licenses its patent portfolio to handset manufacturers and makes royalties from Nokia-branded cellphones. The company, headquartered in Espoo, Finland, operates on a global scale, with most of its revenue from communication service providers.
Read more on NOK →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
